---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-042392"
form_type: "8-K"
ticker: "DSGN"
cik: "0001807120"
company_name: "Design Therapeutics, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:19:22.021771+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Design Therapeutics Reports Q2 2023 Results, Pipeline Progress with DT-216 and DT-168

## Summary
- Initial Phase 1 data for DT-216 in Friedreich Ataxia showed significant dose-related FXN mRNA increase in skeletal muscle (p<0.05)
- DT-216 Phase 1 MAD trial resumed in H2 2024 with improved formulation, data expected H1 2025
- IND submission for DT-168 for Fuchs Endothelial Corneal Dystrophy on track for H2 2023
- Cash and securities of $303.1M as of June 30, 2023, expected to fund operations through 2026
- Net loss of $19.9M for Q2 2023; R&D expenses $17.1M, G&A $5.5M

## SEC filing metadata
- accession: 0000950170-23-042392
- form_type: 8-K
- ticker: DSGN
- cik: 0001807120
- company_name: Design Therapeutics, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1807120/000095017023042392/0000950170-23-042392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1807120/000095017023042392/dsgn-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-042392
- JSON: https://secwatch.observer/filing/0000950170-23-042392.json
- Plain text: https://secwatch.observer/filing/0000950170-23-042392.txt

## Key facts
- Earnings Releases
  Design Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $19.9 million for the quarter ended June 30, 2023..
  - Period: the quarter ended June 30, 2023
  - Net income: Net loss was $19.9 million for the quarter ended June 30, 2023.
  - Result: reported results
  source text: Net loss was $19.9 million for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1807120/000095017023042392/0000950170-23-042392-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.